Document is current

Documents that mention this clinical trial

Single-cell analysis reveals clonally expanded tumor-associated CD57 ⁺ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade
https://doi.org/10.1136/jitc-2022-004759

Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
https://doi.org/10.1136/jitc-2022-004569

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
https://doi.org/10.1016/s0140-6736(16)00561-4

1197 Harnessing the cancer immunity cycle via machine learning models to generate novel strategies for personalized cancer therapy
https://doi.org/10.1136/jitc-2024-sitc2024.1197

Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment
https://doi.org/10.1136/jitc-2022-006643

Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
https://doi.org/10.1136/jitc-2025-013727

Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
https://doi.org/10.1136/jitc-2023-008185

Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade
https://doi.org/10.1136/jitc-2024-010528

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552

Germline whole-exome sequencing reveals <i>FOXP3</i>-related gene variants conferring urinary cancer susceptibility and associated with immune escape
https://doi.org/10.1136/jitc-2024-010417

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
https://doi.org/10.1136/jitc-2020-002231

Documents that mention this clinical trial

Single-cell analysis reveals clonally expanded tumor-associated CD57 ⁺ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade
https://doi.org/10.1136/jitc-2022-004759

Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
https://doi.org/10.1136/jitc-2022-004569

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
https://doi.org/10.1016/s0140-6736(16)00561-4

1197 Harnessing the cancer immunity cycle via machine learning models to generate novel strategies for personalized cancer therapy
https://doi.org/10.1136/jitc-2024-sitc2024.1197

Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment
https://doi.org/10.1136/jitc-2022-006643

Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
https://doi.org/10.1136/jitc-2025-013727

Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
https://doi.org/10.1136/jitc-2023-008185

Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade
https://doi.org/10.1136/jitc-2024-010528

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552

Germline whole-exome sequencing reveals <i>FOXP3</i>-related gene variants conferring urinary cancer susceptibility and associated with immune escape
https://doi.org/10.1136/jitc-2024-010417

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
https://doi.org/10.1136/jitc-2020-002231

Documents that mention this clinical trial

Single-cell analysis reveals clonally expanded tumor-associated CD57 ⁺ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade
https://doi.org/10.1136/jitc-2022-004759

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
https://doi.org/10.1016/s0140-6736(16)00561-4

1197 Harnessing the cancer immunity cycle via machine learning models to generate novel strategies for personalized cancer therapy
https://doi.org/10.1136/jitc-2024-sitc2024.1197

Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
https://doi.org/10.1136/jitc-2025-013727

Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
https://doi.org/10.1136/jitc-2023-008185

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
https://doi.org/10.1136/jitc-2020-002231